Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 77 points (-0.5%) at 16,791 as of Thursday, June 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,231 issues advancing vs. 1,744 declining with 167 unchanged. The Health Care sector currently sits down 0.4% versus the S&P 500, which is down 0.4%. Top gainers within the sector include Vertex Pharmaceuticals ( VRTX), up 1.9%, and Shire ( SHPG), up 0.6%. On the negative front, top decliners within the sector include Intercept Pharmaceuticals ( ICPT), down 4.6%, Community Health Systems ( CYH), down 3.8%, Universal Health Services ( UHS), down 3.7%, HCA Holdings ( HCA), down 2.3% and Grifols ( GRFS), down 1.6%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.90 (2.8%) to $33.19 on average volume. Thus far, 73,222 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 135,900 shares. The stock has ranged in price between $33.08-$33.28 after having opened the day at $33.19 as compared to the previous trading day's close of $32.29. Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. Fresenius Medical Care AG & Co. KGaA has a market cap of $19.3 billion and is part of the health services industry. Shares are down 9.2% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and weak operating cash flow. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.